期刊文献+

大肠癌组织Fas抗原和p53蛋白的表达及临床意义 被引量:3

The Expression and Clinical Significance of Fas Antigen and p53 Protein in Coolorectal Cancer
下载PDF
导出
摘要 目的 探讨大肠癌组织Fas抗原及 p5 3蛋白的表达及临床意义。 方法 采用免疫组织化学方法对 32例大肠癌组织的Fas抗原 ,16例正常大肠组织及 p5 3蛋白表达进行检测和比较。 结果 Fas抗原在正常大肠组织中表达阳性 ,p5 3蛋白在正常大肠组织中表达阴性 ,Fas抗原在大肠癌组织中表达阳性率为 4 0 .6 2 %(13/ 32 ) ,p5 3蛋白在大肠癌组织中的表达阳性率为 5 3.13%。Fas抗原及 p5 3蛋白在大肠癌组织中的表达与患者性别、年龄、肿瘤大小、部位、大体分型、浸润深度、Ducks及局部淋巴结转移等无明显关系 (P >0 .0 5 ) ,Fas抗原在大肠癌组织明显下降 ,Fas抗原表达与大肠癌组织学类型及肝转移相关 (P <0 .0 5 )。p5 3蛋白表达与大肠癌肝转移相关 (P <0 .0 5 )。结论 Fas抗原在大肠癌组织中表达明显下降。随着肿瘤恶性程度的提高 ,Fas抗原表达减少。在肝转移患者中未见表达。p5 3蛋白在大肠癌组织中表达阳性 ,尤以发生肝转移者为著。Fas抗原表达下降或缺乏及 p5 Objective To investigate the clinical significance of Fas antigen and p53 protein expression in patients with colorectal cnecer.Methods Using immunohistochemistry staining,We ohserved Fas antigen and p53 protein expression in 32 cases of colorectal cancer tissue and 16 cases of normal colorectal tissue.Results Fas antigen were positive in 13(40,62%) cases of colorectal cancer.p53 protein was positive in 17(53.13%) cases of colorectal cancer tissue.The expression of Fas antigen and p53protein had no obvius relation to the patients'sex,age,area and depth of invasion,Ducks classfication,size of tumors lymphonodus metastases etc ( P>0.05).Fas antigen was remarkably down regulated in colorectal caincer.The expression of Fas antigen had relation to the type of histopathology and liver metastases ( P<0.05)The over expression of p53 protein was closely associatea with the liver metastases( P<0.05).Conclusion The Fas antigen was remarkably down regulated in colorectal cncer.especiay in patiens with liver metastases.The p53 protein was positive in colorectal cancer especially in patients with liver metastases.The abnormal expression of Fas antigen and p53 protein were associated with poor prognosis.
机构地区 解放军第
出处 《临床军医杂志》 CAS 2003年第1期4-8,共5页 Clinical Journal of Medical Officers
关键词 结直肠肿瘤 FAS抗原 P53蛋白 免疫组织 colorectal cancer Fas antigenl p53 protein Immunohistochemstry
  • 相关文献

参考文献6

二级参考文献9

  • 1PARKIN DM, PISANI P, FERLAY J. Estimates of the worldwide incidence of eighteen major cancers in 1985[J]. Int J Cancer, 1993, 54:594.
  • 2FAN J, DEVESA SS. WEI, et al. Cancer incidence trends in urban Shanghai, 1972~1989[J]. Int J Cancer, 1993, 53:764.
  • 3YAMAGUCHI A, KUROSAKA Y, FUSHIDA S, et al. Expression of P53 protein in colorectal cancer and its relationship to short-term prognosis[J]. Cancer, 1992, 70: 2778.
  • 4SINICROPC FA, RUAN SB, CLEARY KR, et al. Bcl-2 and P53 oncoprotien expression during colorectal tumorigenesis[J]. Cancer Res, 1995, 55:237.
  • 5REMVIKOS Y, TOMINAGA O, HARMMEL P, et al. Increased P53 protein content of colorectal tumors correlates with poor survival[J]. Br J Cancer, 1992, 66: 758.
  • 6LEVINE AJ, MOMAND J, FINLAY CA. The P53 tumor ouppressor gene[J]. Nature, 1991, 351(6326): 453.
  • 7GOTTLIED TM, OREN M. P53 in growth control and neoplasia[J]. Biochem Biophys Acta, 1996, 1287: 77.
  • 8HALL PA, LANE DP. P53 in tumor pathology: Can we trust immunohisto-chemistry[J]? J Pathol, 1994, 172: 1.
  • 9高建军,王为忠,王剑波.大肠癌Fas抗原测定与临床生物学意义的相关研究[J].中华肿瘤杂志,2000,22(4):314-314. 被引量:8

共引文献9

同被引文献40

  • 1Krammer, PH. CD95 (APO-1/Fas) -mediated apoptosis: live and let die [J]. Adv Immunol, 1999, 71: 163-210.
  • 2Sinicrope FA, Hart j, Hsu HA, et al. Apoptotic and mitotic indices predict survival, rates in lymph node-negative colon carcinomas[J]. Clin Cancer Res, 1999, 5 (7) : 1793- 804.
  • 3Liu K, McDuffie E, Abrams SI. Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations [J ]. J Immunol, 2003, 171 (8): 4164-4174.
  • 4Buffer LM, Hewett P J, Buffer WL, et al. Down-regulation of Fas experession in colon cancer is not a result of alletic loss or gene rearrangement [J]. Br J Cancer, 1998, 77 : 1454-1459.
  • 5Rupnarain C, Dlamini Z, Naicker S, et al. Colon cancer: genomics and apoptotic events [J]. Biol Chem, 2004,6:449-464.
  • 6Moiler P, Koretz K, Leihauser F, et al. Expression of APO-1 (CD95) ,a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium[J]. Int J Cancer, 1994,3:371-377.
  • 7Midis GP, Shen Y, Owen Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy[J]. Cancer Res, 1996, 56;3870-3874.
  • 8Yoneharass, Ishii A, Yonehara M, A cell-killing monoclonal abtibody (anti-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor[J]. J Exp Med, 1989,169 : 1747-1749.
  • 9Shibakita M, Tachibana M. Prognostic significance of Fas and Fas ligand expression in human esophageal cancer[J]. Clin Cancer Res, 1999,9:2464-2469.
  • 10Webb SD, Sherratt JA, Fish RG. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 2002;179:113-129.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部